ClinicalTrials.gg
RecruitingNCT05714007Updated Jun 13, 2025

The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery

A Phase 4 interventional study of Ferric derisomaltose and Ferrous succinate in Perioperative Anemia, Surgery and Spinal Deformity, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing iron isomaltoside 1000 in Anemia — 11 open to participants now, 11 under way, 3 of them phase 3. iron isomaltoside 1000 · Anemia.

Planned enrollment
13th of 29
120 · median 120
Started
2023
with 4 others
Phase 4
13 of 29
6 open now
Primary completion
2025-12
later than 1 of 10 live
Registered
21st of 29
by date

Among the 29 studies testing iron isomaltoside 1000 in Anemia, this one is the 13th largest by planned enrollment, is one of 5 that started in 2023, is one of 13 in phase 4, reaches primary completion later than 1 of the 10 other live ones, and was the 21st registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

11 of the 29 studies testing iron isomaltoside 1000 in Anemia are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron isomaltoside 1000 in Anemia, or all of them as a file.
02

Study summary

The prognosis of patients undergoing spinal deformity surgery is often compromised by perioperative anemia due to iron deficiency. The aim of this randomized, controlled trial was to evaluate whether postoperative ferric derisomaltose intravenous injection may improve anemia and prognosis in patients undergoing spinal deformity surgery comparing with oral iron. Participants will be randomly assigned to the treatment group (intravenous ferric derisomaltose) and the control group (oral iron). Changes in hemoglobin concentration, percentage of anemia correction, changes in iron indicators, patient quality of life, and incidence of adverse events will be analyzed to evaluate the efficacy and safety of iron isomaltoside infusion.

Read the detailed description

Iron deficiency is a common cause of perioperative anemia in patients undergoing spinal deformity surgery. Anemia may lead to increased postoperative complications and mortalities, prolonged hospital stays, deteriorated physical function, and severely affect the quality of life.

Oral iron has been widely recommended to treat perioperative anemia. However, the pro-inflammatory cytokines (such as IL-6 (Interleukin-6), TNF-a (Tumor necrosis factor-α)) produced by the inflammatory state after surgery can lead to an increase in hepcidin, which greatly affects the absorption of oral iron. Compared to oral iron, intravenous iron can circumvent the effects of decreased iron absorption in the gastrointestinal tract due to the postoperative inflammatory state and achieve faster and more effective iron supplementation. At present, intravenous iron supplements are mainly second-generation products, including iron sucrose and ferric gluconate. However, the unstable molecular structure of second-generation iron supplements may cause oxidative stress, which limits its administration in large doses.

Compared with traditional intravenous iron, the third-generation iron preparations allow more iron (1000 mg (milligram) or more, no more than 20 mg/kg (kilogram)) to be infused within a short period of time (15-60 minutes), improving patient compliance, reducing costs and complications caused by multiple infusions, and is promising to improve anemia more rapidly. Ferric derisomaltose, as the only third-generation iron currently available in China market, has showed its value in treating anemia in joint replacement surgeries. However, the effectiveness of postoperative intravenous ferric derisomaltose in spinal deformity surgery remains uncertain. Therefore, we designed this prospective randomized trial to evaluate whether intravenous ferric derisomaltose may improve anemia and prognosis in patients undergoing spinal deformity surgery compared with oral iron.

03

Conditions studied

  • Perioperative Anemia
  • Surgery
  • Spinal Deformity
  • Adult

Browse trials for

Keywords

  • spinal deformity surgery
  • perioperative anemia
  • ferric derisomaltose
  • adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Received spinal deformity surgery
  3. 70 g/L ≤ ≤ 110 g/L at POD1, or Hb at POD1 showed a decrease of

    ≥20 g/L compared with baseline

  4. was obtained voluntarily

Exclusion criteria

Exclusion Criteria

  1. Women who are pregnant, breastfeeding, or planning to become pregnant.
  2. known serious to other parenteral iron products
  3. Non-iron deficiency anemia (e.g., hemolytic anemia)
  4. Decompensated liver insufficiency
  5. Coexisting active infection
  6. Drug abuse, including but not limited to opioids, amphetamines, methamphetamine, ketamine, etc.
  7. Other conditions that the investigator considers inappropriate for participation (e.g. deafness, Parkinson's disease, communication disorders, etc.)
  8. Participation in another clinical trial within three months prior to this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Iron to be administered as intravenous ferric derisomaltose: Where Hb (hemoglobin) ≥100 g/L, dosage according to body weight is as follows: Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1000 mg; Body weight ≥70 kg: 1500 mg. Where Hb \<100 g/L, dosage according to body weight is as follows: Body weight \<50 kg: 500mg; Body weight 50 to \<70 kg: 1500mg; Body weight ≥70 kg: 2000 mg. The maximial dose should not exceed 20mg/kg body weight, rounded off to the nearest 100mg

    Drug: Ferric derisomaltose

  • Active comparator
    Control group

    Iron to be administered as oral ferrous succinate: 1 tablet (100 mg) tid (three times daily), starting on the first postoperative day and continuing for 4 weeks.

    Drug: Ferrous succinate

Interventions

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin concentration

    Change in hemoglobin concentrations from POD(postoperative day)1 to POD14

    Time frame: At 14 days

Secondary outcomes

  1. Change in hemoglobin concentration

    Change in hemoglobin concentrations from POD1 to POD5

    Time frame: At 5 days

  2. Change in hemoglobin concentration

    Change in hemoglobin concentrations from POD1 to POD35

    Time frame: At 35 days

  3. Correction of anemia

    The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD5

    Time frame: At 5 days

  4. Correction of anemia

    The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD14

    Time frame: At 14 days

  5. Correction of anemia

    The percentage of effective correction of anemia (elevation of Hb \>20g/L or Hb ≥120g/L) at POD35

    Time frame: At 35 days

  6. Change in serum iron

    Change in serum iron from POD1 to POD5

    Time frame: At 5 days

  7. Change in serum iron

    Change in serum iron from POD1 to POD14

    Time frame: At 14 days

  8. Change in serum iron

    Change in serum iron from POD1 to POD35

    Time frame: At 35 days

  9. Change in ferritin

    Change in ferritin from POD1 to POD5

    Time frame: At 5 days

  10. Change in ferritin

    Change in ferritin from POD1 to POD14

    Time frame: At 14 days

  11. Change in ferritin

    Change in ferritin from POD1 to POD35

    Time frame: At 35 days

  12. Change in transferrin saturation

    Change in transferrin saturation from POD1 to POD5

    Time frame: At 5 days

  13. Change in transferrin saturation

    Change in transferrin saturation from POD1 to POD14

    Time frame: At 14 days

  14. Change in transferrin saturation

    Change in transferrin saturation from POD1 to POD35

    Time frame: At 35 days

  15. Change in soluble transferrin receptor

    Change in soluble transferrin receptor from POD1 to POD5

    Time frame: At 5 days

  16. Change in soluble transferrin receptor

    Change in soluble transferrin receptor from POD1 to POD14

    Time frame: At 14 days

  17. Change in soluble transferrin receptor

    Change in soluble transferrin receptor from POD1 to POD35

    Time frame: At 35 days

  18. EQ-5D

    Quality of life measured by EQ-5D (European Quality of Life-5 Dimensions) at POD5

    Time frame: At 5 days

  19. EQ-5D

    Quality of life measured by EQ-5D at POD14

    Time frame: At 14 days

  20. EQ-5D

    Quality of life measured by EQ-5D at POD35

    Time frame: At 35 days

  21. Fatigue score

    Fatigue measured FACIT-F (The Functional Assessment of Chronic Illness Therapy-Fatigue) questionnaire at POD5

    Time frame: At 5 days

  22. Fatigue score

    Fatigue measured FACIT-F questionnaire at POD14

    Time frame: At 14 days

  23. Fatigue score

    Fatigue measured FACIT-F questionnaire at POD35

    Time frame: At 35 days

  24. Barthel Index

    Independence in daily activities measured by the Barthel questionnaire at POD 5

    Time frame: At 5 days

  25. Barthel Index

    Independence in daily activities measured by the Barthel questionnaire at POD 14

    Time frame: At 14 days

  26. Barthel Index

    Independence in daily activities measured by the Barthel questionnaire at POD 35

    Time frame: At 35 days

  27. Length of hospital stay

    Hospitalized days

    Time frame: At 3 months

  28. Adverse events

    Incidence of adverse events

    Time frame: At 3 months

  29. Infection

    Incidence of postoperative infection

    Time frame: At 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhan J, Jiao Y, Chen W, Huang Y, Shen J. Effects of ferric derisomaltose on postoperative anaemia in adult spinal deformity surgery: a study protocol for a randomised controlled trial. BMJ Open. 2024 Jan 24;14(1):e080952. doi: 10.1136/bmjopen-2023-080952. PubMed 38267243 ↗

Individual participant data

Plan to share: Yes — Coded data is anticipated to be shared with potential collaborators.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Anticipated that data from the study will become available within 5 years after publication of main data.

Access criteria: Data would only be shared with IRB approved collaborators.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2025, 28 months after the start.

Of 60 non-industry phase 4 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 28 months is above that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 17 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 6, 2023
StartActual
Aug 31, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05714007
Collaborators
Pharmacosmos A/S
Responsible party
Weiyun Chen (Principal Investigator, Peking Union Medical College Hospital) — Principal investigator
First posted
Feb 6, 2023
Start date
Aug 31, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jun 13, 2025

Study contacts

Jianxiong Shen, MD
Contact
sjxpumch@163.com
01069152701
Weiyun Chen, MD
Contact
chenweiyun@pumch.cn
13691412863
Weiyun Chen, MD
principal investigator · Peking Union Medical College Hospital
Jianxiong Shen, MD
study director · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion